000256473 001__ 256473
000256473 005__ 20240322115508.0
000256473 0247_ $$2doi$$a10.1007/s00775-022-01986-9
000256473 0247_ $$2pmid$$apmid:36695886
000256473 0247_ $$2pmc$$apmc:PMC9981504
000256473 0247_ $$2ISSN$$a0949-8257
000256473 0247_ $$2ISSN$$a1432-1327
000256473 0247_ $$2altmetric$$aaltmetric:141862152
000256473 037__ $$aDZNE-2023-00335
000256473 041__ $$aEnglish
000256473 1001_ $$aGlykofridi, Pigi$$b0
000256473 245__ $$aSynthesis, structural characterization and study of antioxidant and anti-PrPSc properties of flavonoids and their rhenium(I)-tricarbonyl complexes.
000256473 260__ $$aNew York$$bSpringer$$c2023
000256473 3367_ $$2DRIVER$$aarticle
000256473 3367_ $$2DataCite$$aOutput Types/Journal article
000256473 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711017907_32502
000256473 3367_ $$2BibTeX$$aARTICLE
000256473 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000256473 3367_ $$00$$2EndNote$$aJournal Article
000256473 500__ $$aCC BY
000256473 520__ $$aThis study aims at the synthesis and initial biological evaluation of novel rhenium-tricarbonyl complexes of 3,3',4',5,7-pentahydroxyflavone (quercetin), 3,7,4΄-trihydroxyflavone (resokaempferol), 5,7-dihydroxyflavone (chrysin) and 4΄,5,7-trihydroxyflavonone (naringenin) as neuroprotective and anti-PrP agents. Resokaempferol was synthesized from 2,2΄,4-trihydroxychalcone by H2O2/NaOH. The rhenium-tricarbonyl complexes of the type fac-[Re(CO)3(Fl)(sol)] were synthesized by reacting the precursor fac-[Re(CO)3(sol)3]+ with an equimolar amount of the flavonoids (Fl) quercetin, resokaempferol, chrysin and naringenin and the solvent (sol) was methanol or water. The respective Re-flavonoid complexes were purified by semi-preparative HPLC and characterized by spectroscopic methods. Furthermore, the structure of Re-chrysin was elucidated by X-ray crystallography. Initial screening of the neuroprotective properties of these compounds included the in vitro assessment of the antioxidant properties by the DPPH assay as well as the anti-lipid peroxidation of linoleic acid in the presence of AAPH and their ability to inhibit soybean lipoxygenase. From the above studies, it was concluded that the complexes' properties are mainly correlated with the structural characteristics and the presence of the flavonoids. The flavonoids and their respective Re-complexes were also tested in vitro for their ability to inhibit the formation and aggregation of the amyloid-like abnormal prion protein, PrPSc, by employing the real-time quaking-induced conversion assay with recombinant PrP seeded with cerebrospinal fluid from patients with Creutzfeldt-Jakob disease. All the compounds blocked de novo abnormal PrP formation and aggregation.
000256473 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000256473 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000256473 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000256473 650_7 $$2NLM Chemicals$$aFlavonoids
000256473 650_7 $$2Other$$aAnti-oxidant
000256473 650_7 $$2Other$$aFlavonoids
000256473 650_7 $$2Other$$aLipid peroxidation
000256473 650_7 $$2Other$$aLipoxygenase
000256473 650_7 $$2Other$$aPrion diseases
000256473 650_7 $$2Other$$aRhenium complexes
000256473 650_7 $$2NLM Chemicals$$aAntioxidants
000256473 650_7 $$07440-15-5$$2NLM Chemicals$$aRhenium
000256473 650_7 $$09IKM0I5T1E$$2NLM Chemicals$$aQuercetin
000256473 650_7 $$0BBX060AN9V$$2NLM Chemicals$$aHydrogen Peroxide
000256473 650_7 $$2NLM Chemicals$$a5-deoxykaempferol
000256473 650_7 $$03CN01F5ZJ5$$2NLM Chemicals$$achrysin
000256473 650_7 $$0HN5425SBF2$$2NLM Chemicals$$anaringenin
000256473 650_7 $$2NLM Chemicals$$aPrPSc Proteins
000256473 650_7 $$2NLM Chemicals$$aOrganometallic Compounds
000256473 650_2 $$2MeSH$$aFlavonoids: chemistry
000256473 650_2 $$2MeSH$$aHumans
000256473 650_2 $$2MeSH$$aAntioxidants: pharmacology
000256473 650_2 $$2MeSH$$aRhenium: chemistry
000256473 650_2 $$2MeSH$$aQuercetin
000256473 650_2 $$2MeSH$$aHydrogen Peroxide
000256473 650_2 $$2MeSH$$aCrystallography, X-Ray
000256473 650_2 $$2MeSH$$aFlavonoids: pharmacology
000256473 650_2 $$2MeSH$$aPrPSc Proteins: drug effects
000256473 650_2 $$2MeSH$$aPrPSc Proteins: metabolism
000256473 650_2 $$2MeSH$$aOrganometallic Compounds: chemistry
000256473 650_2 $$2MeSH$$aOrganometallic Compounds: pharmacology
000256473 7001_ $$aTziouri, Vassiliki-Eleni$$b1
000256473 7001_ $$aXanthopoulos, Konstantinos$$b2
000256473 7001_ $$aVlachou, Maria-Eirini$$b3
000256473 7001_ $$0P:(DE-2719)9000766$$aSilva-Correia, Susana$$b4$$udzne
000256473 7001_ $$0P:(DE-2719)9001954$$aFischer, Anna-Lisa$$b5$$udzne
000256473 7001_ $$0P:(DE-2719)2811840$$aThüne, Katrin$$b6$$udzne
000256473 7001_ $$aHatzidimitriou, Antonios$$b7
000256473 7001_ $$0P:(DE-2719)2000058$$aZerr, Inga$$b8$$udzne
000256473 7001_ $$0P:(DE-2719)9000287$$aSchmitz, Matthias$$b9$$udzne
000256473 7001_ $$aSklaviadis, Theodoros$$b10
000256473 7001_ $$aHadjipavlou-Litina, Dimitra$$b11
000256473 7001_ $$00000-0002-7833-8744$$aPapagiannopoulou, Dionysia$$b12
000256473 773__ $$0PERI:(DE-600)1464026-0$$a10.1007/s00775-022-01986-9$$gVol. 28, no. 2, p. 235 - 247$$n2$$p235 - 247$$tJournal of biological inorganic chemistry$$v28$$x0949-8257$$y2023
000256473 8564_ $$uhttps://pub.dzne.de/record/256473/files/DZNE-2023-00335.pdf$$yOpenAccess
000256473 8564_ $$uhttps://pub.dzne.de/record/256473/files/DZNE-2023-00335.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000256473 909CO $$ooai:pub.dzne.de:256473$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000256473 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000766$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000256473 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001954$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000256473 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811840$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000256473 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000058$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000256473 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000287$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000256473 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000256473 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000256473 9141_ $$y2023
000256473 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000256473 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000256473 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000256473 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-09
000256473 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000256473 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ BIOL INORG CHEM : 2022$$d2023-10-21
000256473 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000256473 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-09
000256473 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-09$$wger
000256473 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000256473 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
000256473 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000256473 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000256473 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-10-21
000256473 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-09
000256473 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000256473 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000256473 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarker$$x0
000256473 9201_ $$0I:(DE-2719)5000037$$kExt UMG Zerr$$lExt UMG Zerr$$x1
000256473 9201_ $$0I:(DE-2719)1410002$$kAG Fischer$$lEpigenetics and Systems Medicine in Neurodegenerative Diseases$$x2
000256473 980__ $$ajournal
000256473 980__ $$aVDB
000256473 980__ $$aUNRESTRICTED
000256473 980__ $$aI:(DE-2719)1440011-1
000256473 980__ $$aI:(DE-2719)5000037
000256473 980__ $$aI:(DE-2719)1410002
000256473 9801_ $$aFullTexts